Table 2.
Univariate and multivariate competing risk analyses to identify independent risk factors of OS in patients with unresectable HCC treated with lenvatinib monotherapy or lenvatinib plus ICI.
| Variable | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Gender (female) | 0.84 (0.51-1.39) | 0.497 | NA | NA |
| Age (>50 years) | 0.86 (0.62-1.21) | 0.389 | NA | NA |
| Etiology (HBV) | 0.55 (0.33-0.93) | 0.025 | 0.74 (0.43-1.27) | 0.277 |
| ECOG (1 score) | 0.75 (0.49-1.15) | 0.188 | NA | NA |
| Child-Pugh stage (B) | 1.27 (0.72-2.25) | 0.408 | NA | NA |
| Tumor size (> 10 cm) | 1.47 (1.05-2.07) | 0.026 | 1.11 (0.77-1.61) | 0.569 |
|
Tumor number
(>3 lesions) |
0.93 (0.78-1.11) | 0.430 | NA | NA |
| MVI | 1.27 (0.91-1.78) | 0.156 | NA | NA |
| Metastasis | 1.82 (1.32-2.51) | <0.001 | 2.07 (1.49-2.87) | <0.001 |
| AFP (> 100ng/mL) | 1.47 (1.06-2.04) | 0.020 | 1.22 (0.87-1.71) | 0.254 |
|
PIVKA-II
(>600 mAU/mL) |
2.17 (1.51-3.13) | <0.001 | 2.05 (1.36-3.08) | 0.001 |
AFP, alpha-fetoprotein; BCLC stage, Barcelona Clinic Liver Cancer; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HR, hazard ratio; NA, not applicable; MVI, macrovascular invasion; PIVKA-II, Protein Induced by Vitamin K Absence or Antagonist-II.